Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have spe…
Biotechnology
US, Boston [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -12.20 | 3.50 | 3.99 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 24.52 | -7.09 | -9.40 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 5.29 | 71.83 | 68.22 | |
| Cash | -9.53 | 39.39 | 43.54 | |
| Capex | -113.54 | -0.96 | -0.45 | |
| Free Cash Flow | 791.27 | 4.10 | 0.46 | |
| Revenue | 6.53 | 10.41 | 9.77 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 2.19 | 0.87 | 0.85 | |
| Operating Margin | 11.01 | 0.42 | 0.38 | |
| ROA | 7.87 | 0.05 | 0.04 | |
| ROE | 7.59 | 0.06 | 0.06 | |
| ROIC | 15.15 | 0.05 | 0.04 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of VRTX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of VRTX is permitted for members.
6
Leverage & Liquidity